scholarly journals Effective treatment of COVID-19 pneumonia with the Chinese herbal decoction FeiDuQing: A retrospective cohort study

2021 ◽  
Author(s):  
Weiwu Wang ◽  
Bo Fu ◽  
Wumin Xu ◽  
Shuilin Chen ◽  
Tao Liu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Survival Rates ◽  
Cure Rate ◽  
Chinese Herbal ◽  
Herbal Decoction ◽  
Duration Of Hospitalization ◽  
Global Population

Abstract Background The coronavirus disease (COVID-19) pandemic has had catastrophic consequences globally. Nevertheless, the majority of the global population has not been vaccinated against the disease, and available treatments are limited. FeiDuQing (FDQ), a Chinese medicinal decoction widely used for COVID-19 pneumonia in Xianning City, China, has a cure rate of 98.21%. Therefore, evaluating the role of FDQ in successfully treating patients with COVID-19 is crucial. Methods In this retrospective cohort study, 355 consecutive patients who developed COVID-19 pneumonia between January 15 and February 18, 2020 were included; among them, 213 received FDQ. Data on the demographic characteristics, length of hospitalizations, symptoms at admission and discharge, adverse events, and laboratory parameters were analyzed. Results In contrast to patients who received FDQ, 12 patients who did not receive FDQ (8.45%) developed severe conditions, and one of them died. Furthermore, FDQ treatment was associated with a shortened duration of hospitalization (18.2 vs. 22.1 days, P < 0.0001), even in elderly patients aged > 60 years (18.0 days vs. 26.1 days, P < 0.0001). At discharge, three (1.40%) patients treated with FDQ had mild symptoms, whereas 16 (11.19%) patients not treated with FDQ had various symptoms. The cumulative survival rates of patients treated with FDQ and those not treated with FDQ were 79.04% and 32.60%, respectively (hazard ratio: 0.210, 95% confidence interval: 0.123–0.357, P < 0.001). Additionally, FDQ had no severe adverse effects. Conclusions Our findings suggest that FDQ is a potential therapeutic candidate for fighting COVID-19.

The duration of hospitalization before review by the rapid response team: A retrospective cohort study

2015 ◽  
Vol 30 (4) ◽  
pp. 692-697 ◽  
Author(s):  
Roger J. Smith ◽  
John D. Santamaria ◽  
Espedito E. Faraone ◽  
Jennifer A. Holmes ◽  
David A. Reid ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Rapid Response Team ◽  
Rapid Response ◽  
Response Team ◽  
Duration Of Hospitalization

scholarly journals Role of quality measurement in inappropriate use of screening for colorectal cancer: retrospective cohort study

BMJ ◽  
2014 ◽  
Vol 348 (feb26 2) ◽  
pp. g1247-g1247 ◽  
Author(s):  
S. D. Saini ◽  
S. Vijan ◽  
P. Schoenfeld ◽  
A. A. Powell ◽  
S. Moser ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Quality Measurement ◽  
Inappropriate Use

scholarly journals Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Maryam Dehghani ◽  
Zahra Davoodi ◽  
Farahnaz Bidari ◽  
Amin Momeni Moghaddam ◽  
Davood Khalili ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Cohort Study ◽  
Cavernous Sinus ◽  
Retrospective Cohort Study ◽  
Pituitary Adenomas ◽  
Retrospective Cohort ◽  
Remission Rate ◽  
Cavernous Sinus Invasion ◽  
Dual Staining

Abstract Background Regarding the inconclusive results of previous investigations, this study aimed to determine the association between pathology, as a possible predictor, with remission outcomes, to know the role of pathology in the personalized decision making in acromegaly patients. Methods A retrospective cohort study was performed on the consecutive surgeries for growth hormone (GH) producing pituitary adenomas from February 2015 to January 2021. Seventy-one patients were assessed for granulation patterns and prolactin co-expression as dual staining adenomas. The role of pathology and some other predictors on surgical remission was evaluated using logistic regression models. Results Among 71 included patients, 34 (47.9%) patients had densely granulated (DG), 14 (19.7%) had sparsely granulated (SG), 23 (32.4%) had dual staining pituitary adenomas. The remission rate was about 62.5% in the patients with SG and DG adenomas named single staining and 52.2% in dual staining groups. Postoperative remission was 1.53-folds higher in the single staining adenomas than dual staining-one (non-significant). The remission rate was doubled in DG group compared to two other groups (non-significant). By adjusting different predictors, cavernous sinus invasion and one-day postoperative GH levels decreased remission rate by 91% (95% CI: 0.01–0.67; p = 0.015) and 64% (95% CI: 0.19–0.69; p < 0.001), respectively. Responses to the medications were not significantly different among three groups. Conclusion Various pathological subtypes of pituitary adenomas do not appear to have a predictive role in estimating remission outcomes. Cavernous sinus invasion followed by one-day postoperative GH is the strongest parameter to predict biochemical remission.

scholarly journals Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1568 ◽  
Author(s):  
Maria N. Chitasombat ◽  
Siriorn P. Watcharananan
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Antithymocyte Globulin ◽  
Graft Loss ◽  
Infectious Complications ◽  
Inpatient Setting ◽  
Cost Of Treatment ◽  
Duration Of Hospitalization ◽  
Cmv Reactivation

Background: Cytomegalovirus (CMV) is an important cause of infectious complications after kidney transplantation (KT), especially among patients receiving antithymocyte globulin (ATG). CMV infection can result in organ dysfunction and indirect effects such as graft rejection, graft failure, and opportunistic infections. Prevention of CMV reactivation includes pre-emptive or prophylactic approaches. Access to valganciclovir prophylaxis is limited by high cost. Our objective is to determine the burden and cost of treatment for CMV reactivation/disease among KT recipients who received ATG in Thailand since its first use in our center. Methods: We conducted a single-center retrospective cohort study of KT patients who received ATG during 2010-2013. We reviewed patients’ characteristics, type of CMV prophylaxis, incidence of CMV reactivation, and outcome (co-infections, graft function and death). We compared the treatment cost between patients with and without CMV reactivation. Results: Thirty patients included in the study had CMV serostatus D+/R+. Twenty-nine patients received intravenous ganciclovir early after KT as inpatients. Only three received outpatient valganciclovir prophylaxis. Incidence of CMV reactivation was 43%, with a median onset of 91 (range 23-1007) days after KT. Three patients had CMV end-organ disease; enterocolitis or retinitis. Infectious complication rate among ATG-treated KT patients was up to 83%, with a trend toward a higher rate among those with CMV reactivation (P = 0.087). Patients with CMV reactivation/disease required longer duration of hospitalization (P = 0.018). The rate of graft loss was 17%. The survival rate was 97%. The cost of treatment among patients with CMV reactivation was significantly higher for both inpatient setting (P = 0.021) and total cost (P = 0.035) than in those without CMV reactivation. Conclusions: Burden of infectious complications among ATG-treated KT patients was high. CMV reactivation is common and associated with longer duration of hospitalization and higher cost.

Sign in / Sign up

Export Citation Format

Share Document